热门资讯> 正文
FDA主要官员离职后，uniQure激增
2026-03-09 21:01
- Despite a US FDA official criticizing uniQure (QURE) on March 5 for the way it conducted a study for Huntington's disease asset AMT-130, the stock is surging ~36% in premarket trading Monday.
- That official, in a call with reporters, accused uniQure of "performing a distorted or manipulated comparison" in its phase 1/2 trial, which it had intended to use for its application with the FDA. The agency has requested the company conduct a phase 3 trial.
- However, since the official's comments, uniQure's share price has fared well, closing up ~18% on March 5. It added another ~34% on March 6.
- UniQure's fortune likely changed for the better due to the announcement on March 6 that Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research (CBER), will be departing the agency in April. Prasad oversaw the agency's handling of AMT-130.
More on uniQure
- uniQure: Worst Case Scenario Becomes Reality
- uniQure: The Worst Case Scenario Just Got Official (Rating Downgrade)
- uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
- uniQure used 'distorted comparison' in Huntington's asset trial: FDA official
- uniQure plummets as FDA calls for phase 3 trial for Huntington's asset AMT-130
推荐文章
美股机会日报 | 特朗普再放豪言！正与伊朗谈判，并收到伊方“大礼”；特斯拉机器人再迎新进展！马斯克称有望明年实现量产
一图看懂 | 单季盈利承压！拼多多Q4营收1239亿元同比增12%，调后净利却下跌12%；高管称“力争三年再造一个拼多多”
财报前瞻 | 美团Q4财报将放榜！大摩、高盛逆势力挺股价，当前美团已严重超跌？
中东战火中金价狂泻11%！创43年最惨周跌，避险逻辑崩塌还是黄金坑？
美股机会日报 | 中东硝烟将散？以官员称美方4月9日结束对伊战争！海力士拟筹资百亿赴美上市，豪掷80亿美元锁定阿斯麦光刻机！
一图看懂 | 连续5个季度破千亿！小米Q4营收1169亿创历史新高；净利大增43.8%至63亿元
无论美伊谈判真假！华尔街已从特朗普引发的五分钟狂飙获得明确信号？
麦格理：紧张局势缓和后布伦特原油底部在每桶85至90美元
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
